Jun 10, 2017
Multiple Myeloma Celgene
C O N T E N T S:
KEY TOPICS
The biotech company and its partner, Celgene, released updated clinical results from an ongoing study of patients with relapsed/refractory multiple myeloma, a blood cancer.(More…)
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.(Mor…
View On WordPress